Stem Cell and Tissue Re-engineering Program, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia.
King Faisal Cancer Center, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia.
Bone Marrow Transplant. 2018 Sep;53(9):1170-1179. doi: 10.1038/s41409-018-0123-7. Epub 2018 Mar 16.
NK cell activity is tuned by a balance of activating and inhibitory signals transmitted via their respective receptors, including killer immunoglobulin-like receptors (KIRs). The impact of NK cells on graft-versus-leukemia following hematopoietic stem cell transplantation (HSCT) is well established. These effects sometimes lead to GvHD. The link between KIR/HLA interaction and GvHD remains unclear. Herein, we studied the impact of the KIR/HLA interaction on HSCT outcomes in a longitudinal follow-up study of a highly consanguineous HLA-matched related cohort. Peripheral blood DNA was collected from HSCT donor-recipient pairs (n = 87), including 41 AML pairs. KIR and HLA were genotyped and significant results were only measured when matching KIR (donor) with HLA (recipients). GvHD was observed in 47% of patients. KIR2DL1_C2 and 2DS2_C1 (P = 0.02 and 0.04, respectively) matching was associated with an increased incidence of acute GvHD in AML donor-recipient pairs. The rate of chronic GvHD also rose in AML patients who were matched for KIR2DS1_C2 (P = 0.004) and had either KIR2DL2 or KIR2DS2 (P = 0.03). In conclusion, matching of KIR2DL1, 2DS1, and 2DS2 in donors with their HLA-C ligands in recipients is associated with increased GvHD, and holds potential for selection of HSCT donors.
NK 细胞的活性受其各自受体传递的激活和抑制信号的平衡调节,包括杀伤免疫球蛋白样受体(KIR)。NK 细胞在造血干细胞移植(HSCT)后对移植物抗白血病的影响已得到充分证实。这些影响有时会导致移植物抗宿主病(GvHD)。KIR/HLA 相互作用与 GvHD 之间的联系尚不清楚。在此,我们通过对高度同血缘 HLA 匹配相关队列的纵向随访研究,研究了 KIR/HLA 相互作用对 HSCT 结果的影响。从 HSCT 供受者对(n=87)中采集外周血 DNA,包括 41 对 AML 对。对 KIR 和 HLA 进行基因分型,仅在匹配 KIR(供体)与 HLA(受体)时测量显著结果。47%的患者观察到 GvHD。KIR2DL1_C2 和 2DS2_C1(P=0.02 和 0.04)匹配与 AML 供受者对急性 GvHD 的发生率增加相关。KIR2DS1_C2 匹配的 AML 患者的慢性 GvHD 发生率也升高(P=0.004),并且存在 KIR2DL2 或 KIR2DS2(P=0.03)。总之,供体中 KIR2DL1、2DS1 和 2DS2 与其 HLA-C 配体的匹配与 GvHD 增加相关,并有可能用于 HSCT 供体的选择。